Mean apparent diffusion coefficient in a single slice may predict tumor response to whole-brain radiation therapy in non-small-cell lung cancer patients with brain metastases

被引:3
|
作者
Zhao, Lihao [1 ]
Zhao, Mengjing [2 ]
Liu, Jinjin [2 ]
Yang, Han [1 ]
Zhou, Xiaojun [2 ]
Wen, Caiyun [2 ]
Li, Gang [1 ]
Duan, Yuxia [2 ]
机构
[1] Wenzhou Med Univ, Dept Chemoradiat Oncol, Affiliated Hosp 1, 2 Fuxue Lane, Wenzhou 325000, Peoples R China
[2] Wenzhou Med Univ, Dept Radiol, Affiliated Hosp 1, South Baixiang St, Wenzhou 325000, Peoples R China
关键词
Diffusion magnetic resonance imaging; Radiotherapy; Brain neoplasms; Carcinoma; non-small-cell lung; Treatment outcome; STEREOTACTIC RADIOSURGERY; SUPPORTIVE CARE; WEIGHTED MRI; RADIOTHERAPY; CHEMORADIOTHERAPY; TOMOGRAPHY; MANAGEMENT; SURVIVAL;
D O I
10.1007/s00330-020-07584-0
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objectives This study aimed to access the performance of apparent diffusion coefficient (ADC) as a predictor for treatment response to whole-brain radiotherapy (WBRT) in patients with brain metastases (BMs) from non-small-cell lung cancer (NSCLC). Methods A retrospective analysis was conducted of 102 NSCLC patients with BMs who underwent WBRT between 2012 and 2016. Diffusion-weighted MRI were performed pre-WBRT and within 12 weeks after WBRT started. Mean single-plane ADC value of ROIs was evaluated by two radiologists blinded to results of each other. The treatment response rate, intracranial progression-free survival (PFS), and overall survival (OS) were analyzed based on the ADC value and Delta ADC respectively. At last, we used COX and logistic regression to do the multivariate analysis. Results There was good inter-observer agreement of mean ADC value pre-WBRT, post-WBRT, and Delta ADC between the 2 radiologists (Pearson correlation 0.915 [pre-WBRT], 0.950 [post-WBRT], 0.937 [Delta ADC], p < 0.001, for each one). High mean ADC value were related with better response rate (72.2% vs 37.5%, p = 0.001) and iPFS (7.6 vs 6.4 months, p = 0.031). High Delta ADC were related with better response rate (73.6% vs 36.7%, p < 0.001). Multivariate analysis shows that histopathology, BMs number, high ADC value pre-WBRT, and high Delta ADC post-WBRT were related to better treatment response of WBRT, and KPS, BMs number, and low ADC value pre-WBRT increased the risk of developing intracranial relapse. ConclusionsThe mean single-plane ADC value pre-WBRT and Delta ADC post-WBRT were potential predictor for intracranial tumor response to WBRT in NSCLC patients with brain metastases. Key Points ADC value is a potential predictor of intracranial treatment response to WBRT in NSCLC patients with brain metastases. Higher mean ADC value pre-WBRT and.ADC post-WBRT of brain metastases were related to better intracranial tumor response. Prediction of response before WBRT using ADC value can help oncologists to make better therapy plans and avoid missing opportunities for rescue therapy.
引用
收藏
页码:5565 / 5575
页数:11
相关论文
共 50 条
  • [31] Brain Metastases in Non-Small-Cell Lung Cancer
    Dawe, David E.
    Greenspoon, Jeffrey N.
    Ellis, Peter M.
    CLINICAL LUNG CANCER, 2014, 15 (04) : 249 - 257
  • [32] Targeted Therapy as an Alternative to Whole-Brain Radiotherapy in EGFR-Mutant or ALK-Positive Non-Small-Cell Lung Cancer With Brain Metastases
    Martinez, Pablo
    Mak, Raymond H.
    Oxnard, Geoffrey R.
    JAMA ONCOLOGY, 2017, 3 (09) : 1274 - 1275
  • [33] Anti-PD1 Therapy Plus Whole-Brain Radiation Therapy May Prolong PFS in Selected Non-Small Cell Lung Cancer Patients with Brain Metastases: A Retrospective Study
    Khan, Muhammad
    Zhao, Zhihong
    Li, Xianming
    Liao, Guixiang
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2021, 14 : 8903 - 8918
  • [34] Association of response to whole-brain irradiation of brain metastases with molecular profile in non-small cell lung cancer.
    Arrieta, Oscar
    Caballe-Perez, Enrique
    Ramirez-Tirado, Alejandra
    Mejia-Perez, Alberto
    Blake, Monika
    Flores-Estrada, Diana
    Macedo-Perez, Eleazar Omar
    Zorrilla, Andres Felipe Cardona
    De La Garza, Jaime G.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [35] Combining Whole-Brain Radiotherapy with Gefitinib/Erlotinib for Brain Metastases from Non-Small-Cell Lung Cancer: A Meta-Analysis
    Zheng, Mao-hua
    Sun, Hong-tao
    Xu, Ji-guang
    Yang, Gang
    Huo, Lei-ming
    Zhang, Pan
    Tian, Jin-hui
    Yang, Ke-hu
    BIOMED RESEARCH INTERNATIONAL, 2016, 2016
  • [36] Reply to Comparative Effectiveness of Stereotactic Radiosurgery Versus Whole-Brain Radiation Therapy for Patients With Brain Metastases From Breast or Non-Small Cell Lung Cancer
    Halasz, Lia M.
    Uno, Hajime
    Punglia, Rinaa S.
    CANCER, 2016, 122 (20) : 3244 - 3245
  • [37] The Assessment of Cognitive Function in Lung Cancer Patients With Brain Metastases Before and After Whole-Brain Radiation Therapy
    Zhou, M.
    Zou, L.
    Chen, Q. Q.
    Tian, Y.
    Lian, Y. X.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : E68 - E69
  • [38] Effects of Whole-Brain Radiation Therapy and Other Factors on Survival in Patients with Brain Metastases From Lung Cancer
    Li, Z.
    Zhang, J.
    Shen, D.
    Yang, F.
    Kong, D.
    Kong, J.
    Zhang, J.
    Zhang, A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : E474 - E474
  • [39] Erlotinib therapy in a patient with non-small-cell lung cancer and brain metastases
    Giuseppe Altavilla
    Carmela Arrigo
    Maria Carmela Santarpia
    Giuseppe Galletti
    Giovanni Picone
    Grazia Marabello
    Chiara Tomasello
    Vincenzo V. Pitini
    Journal of Neuro-Oncology, 2008, 90 : 31 - 33
  • [40] Erlotinib therapy in a patient with non-small-cell lung cancer and brain metastases
    Altavilla, Giuseppe
    Arrigo, Carmela
    Santarpia, Maria Carmela
    Galletti, Giuseppe
    Picone, Giovanni
    Marabello, Grazia
    Tomasello, Chiara
    Pitini, Vincenzo V.
    JOURNAL OF NEURO-ONCOLOGY, 2008, 90 (01) : 31 - 33